A restropective observational study of fixed dose combination of Salmeterol/fluticasone-propionate and Umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease (COPD)
Latest Information Update: 27 Jun 2023
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary) ; Umeclidinium/vilanterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
Most Recent Events
- 18 Sep 2019 New trial record